- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03350711
A Screening and Recruitment Study in Adults Expressing Interest in the Emory Microbiota Enrichment Program (MEP)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The unintended consequence of the development of life-saving antimicrobial therapies has been the havoc that is wreaked on the patient's intestinal microbiota. Clostridium difficile infection (CDI) has been found to be the causative agent of 15%-25% of all cases of antibiotic-associated diarrhea, with increasing severity in those with advanced age and who are hospitalized for other reasons. Despite resolution of symptoms in patients treated with antimicrobials, there remains an ~20% CDI recurrence rate. Furthermore, patients who experience a first recurrence have a 40% risk of an additional recurrence and those with two or more episodes face a 60% risk. As a result, there are substantial numbers of patients who live with chronic and debilitating diarrhea from CDI despite repeated courses of prolonged therapy. C. difficile infection represents an important clinical syndrome and development of new preventive and therapeutic strategies are a key unmet medical need.
Fecal microbiota transplant (FMT), which is defined as the transfer of the feces from one individual (donor) into another individual (recipient), has recently become more standardized and acceptable for the treatment of C. difficile. The first randomized controlled trial (RCT) was published in January of 2013 and compared duodenal infusion FMT after oral vancomycin as compared to oral vancomycin alone and for the treatment of recurrent C. difficile. The trial showed excellent efficacy for FMT, along with restoration of the diversity of the microbiota in the recipients. Even prior to this RCT, case series with over 200 patients had shown excellent efficacy with one FMT, with rates of success almost to 90% when patients received two FMTs.
Emory's Fecal Transplant Program was started in 2012, and since then has performed 280 FMTs in inpatient and outpatient settings. The Emory Microbiota Enrichment Program (MEP) came into existence in 2016 in order to provide a clinical research infrastructure to recruit subjects into clinical research studies related to the microbiome. The goal of this protocol is to create an electronic database capture with a survey to capture demographic and medical information about subjects reaching out to obtain FMT for a variety of reasons and, if needed, pre-screen these subjects for current and upcoming protocols within MEP. A list of potential participants will be generated using the Emory University Data Warehouse to identify subjects with CDI and other conditions that could benefit from the Emory MEP. Advertisements will be placed in the community as a recruitment tool and individuals that contact Emory will be connected to the study recruiter. The recruiters will review the eligibility criteria for inclusion in the MEP database as well as the inclusion and exclusion criteria for all of the enrolling FMT studies currently underway at the Hope Clinic and Emory University Hospitals. If the subject meets the inclusion criteria for one of the Emory FMT studies, they will be invited for a general screening visit or a study specific screening visit for a specific MEP protocol.
The duration of the study varies for each subject and participation is indefinite unless one of the following occurs:
- A subject is rendered ineligible
- The screening is completed, and a subject is referred to a specific MEP study.
- A subject withdraws consent to participate in this study, which may be done verbally or by revocation letter. Additional details will be requested to determine if the participant either no longer wants to perform any MEP related activities (e.g., MEP survey) or revokes the future use of protected health information (PHI) and medical chart review during follow-up.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Colleen S Kraft, MD, MSc
- Phone Number: 678-487-9766 (OPT-4-TRY-POO)
- Email: microbiota.enrichment@emory.edu
Study Contact Backup
- Name: Jennifer Truell
- Phone Number: 404-778-0014
- Email: jennifer.carter.truell@emory.edu
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Recruiting
- Emory Clinic
-
Contact:
- Jennifer Truell
- Phone Number: 404-778-0014
- Email: jennifer.carter.truell@emory.edu
-
Contact:
- Allen W Graham
- Phone Number: 404-712-2962
- Email: allen.w.graham@emory.edu
-
Atlanta, Georgia, United States, 30322
- Recruiting
- Emory Hospital
-
Contact:
- Jennifer Truell
- Phone Number: 404-778-0014
- Email: jennifer.carter.truell@emory.edu
-
Contact:
- Allen W Graham
- Phone Number: 404-712-2962
- Email: allen.w.graham@emory.edu
-
Decatur, Georgia, United States, 30030
- Recruiting
- The Hope Clinic of the Emory Vaccine Center
-
Contact:
- Jennifer Truell
- Phone Number: 404-778-0014
- Email: jennifer.carter.truell@emory.edu
-
Contact:
- Allen W Graham
- Phone Number: 404-712-2962
- Email: allen.w.graham@emory.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age of at least 18 years
Seeking services that are affiliated with the Emory Microbiota Enrichment Program (MEP) for any reason, such as:
- Clinical services, interventions, or procedures (e.g., FMT), or
- Research studies
- Able to understand and approve the informed consent and HIPAA authorizations forms verbally on the phone or by signature in-person
Exclusion Criteria:
- Known or suspected terminal disease
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Microbiota Enrichment Program (MEP)
Patients who are seeking a fecal microbiota transplant (FMT), for any reason, who will be part of a registry of patients to potentially screen for a FMT study.
|
Registry participants will provide demographic and medical information and may take part in general screening procedures to facilitate enrolling into an appropriate FMT study. Once determined to be eligible for study entry, study-specific screening procedures may include:
Participants will be re-screened every 6 months and will remain in follow-up indefinitely or until they are rendered ineligible, participate in a MEP study, or withdraw consent to be included in the database. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To determine if the creation of a database will improve enrollment onto other research studies
Time Frame: Ten years
|
Successful creation of the database will be defined as capturing demographic and medical information about persons reaching out to obtain FMT in order to screen them for current and upcoming protocols within MEP.
|
Ten years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Colleen Kraft, MD, MSc, Emory University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00098240
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Clostridium Difficile Infection
-
Vedanta Biosciences, Inc.CompletedClostridium Difficile Infection | Clostridium Difficile Infection Recurrence | Clostridium Difficile | CDI | Clostridioides Difficile Infection | Clostridioides Difficile | Clostridioides Difficile Infection RecurrenceUnited States, Canada
-
Vedanta Biosciences, Inc.Not yet recruitingClostridium Difficile Infection Recurrence | Recurrent Clostridium Difficile Infection | Clostridium Difficile | Diarrhea Infectious | CDI | Clostridium Difficile Infections | Clostridioides Difficile Infection | C.Difficile Diarrhea | Clostridioides Difficile Infection Recurrence | C. Diff Infection
-
University of PennsylvaniaTerminatedSevere Clostridium Difficile Infection | Severe-Complicated/Fulminant Clostridium Difficile InfectionUnited States
-
Mikrobiomik Healthcare Company S.L.CompletedRecurrent Clostridium Difficile Infection | Primary Clostridium Difficile InfectionSpain
-
University Health Network, TorontoTerminatedRecurrent Clostridium Difficile Infection | Laboratory Confirmed Clostridium Difficile InfectionCanada
-
University of North Carolina, Chapel HillNorth Carolina Translational and Clinical Sciences Institute; North Carolina...CompletedClostridium DifficileUnited States
-
University of Wisconsin, MadisonAgency for Healthcare Research and Quality (AHRQ)Enrolling by invitationClostridium Difficile Infection | Clostridium Difficile | C Difficile ColitisUnited States
-
MJM BontenUniversiteit Antwerpen; Universitätsklinikum Köln; Da VolterraCompletedClostridium DifficileGermany, Spain, France, Greece, Netherlands, Romania
-
Astellas Pharma Europe Ltd.Cubist Pharmaceuticals LLCTerminatedClostridium DifficileSpain, France, Germany, Greece, Denmark, Austria, Poland
-
Chinese University of Hong KongUnknownClostridium Difficile Infection | Clostridium DifficileHong Kong
Clinical Trials on Microbiota Enrichment Program (MEP)
-
University of Southern CaliforniaRecruiting
-
Istituto Superiore di SanitàUniversity of Roma La SapienzaCompletedAutism Spectrum DisorderItaly
-
National Taiwan University HospitalRecruitingAutism Spectrum DisorderTaiwan
-
Centre for Interdisciplinary Research in Rehabilitation...Fonds de la Recherche en Santé du QuébecCompletedTBI (Traumatic Brain Injury) | Aging | RehabilitationCanada
-
University of Wisconsin, MilwaukeeNF Midwest; NF NortheastRecruitingSocial Skills | Neurofibromatosis 1United States
-
Marquette UniversityActive, not recruitingAutism Spectrum Disorder | Autism | Asperger Disorder | PDD-NOSUnited States
-
National Taiwan University HospitalRecruitingSocial Skill Training GroupTaiwan
-
Chinese University of Hong KongCompletedType 2 Diabetes Mellitus | Type2 Diabetes | ObeseHong Kong
-
Children's Hospital Medical Center, CincinnatiUnited States Department of DefenseActive, not recruitingAutism Spectrum DisorderUnited States
-
Children's Hospital Medical Center, CincinnatiEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedAutism Spectrum DisorderUnited States